← Back to Clinical Trials
Recruiting NCT05654246

NCT05654246 Susan G. Komen's ShareForCures

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05654246
Status Recruiting
Phase
Sponsor Susan G. Komen Breast Cancer Foundation
Condition Breast Cancer
Study Type OBSERVATIONAL
Enrollment 200,000 participants
Start Date 2022-11-17
Primary Completion 2032-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200,000 participants in total. It began in 2022-11-17 with a primary completion date of 2032-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

ShareForCures (SFC) is a community-based participatory research registry, and its prime objective is to engage participants representative of the United States breast cancer patient population -including minoritized and historically marginalized people, persons, or communities-to ensure the data researchers use to study breast cancer is as diverse as the people touched by this disease. In doing so, researchers will have a better understanding of breast cancer, and everyone can potentially benefit from scientific advances and improvements in care.

Eligibility Criteria

Inclusion Criteria: * Individuals must be at least 18 years old. (Individuals in Alabama and Nebraska must be over 19 and individuals in Mississippi and Pennsylvania must be over 21 to participate). * Individuals must have been diagnosed with cancer originating (or is suspected to originate) from the breast. * Individuals must be currently residing in the United States or a territory of the United States. * Individuals must be able to read and understand English. Exclusion Criteria: * Individuals under the age of 18 years. (Individuals in Alabama and Nebraska under 19 and individuals in Mississippi and Pennsylvania under 21 are not eligible to participate). * Individuals without a diagnosis of breast cancer. * Individuals who are not residing in the United States or a territory of the United States. * Individuals unable to read and understand English.

Contact & Investigator

Central Contact

Jerome Jourquin, Ph.D., M.S.

✉ JJourquin@komen.org

📞 1-877-465-6636

Principal Investigator

Jerome Jourquin, Ph.D., M.S.

PRINCIPAL INVESTIGATOR

Susan G. Komen

Frequently Asked Questions

Who can join the NCT05654246 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05654246 currently recruiting?

Yes, NCT05654246 is actively recruiting participants. Contact the research team at JJourquin@komen.org for enrollment information.

Where is the NCT05654246 trial being conducted?

This trial is being conducted at Dallas, United States.

Who is sponsoring the NCT05654246 clinical trial?

NCT05654246 is sponsored by Susan G. Komen Breast Cancer Foundation. The principal investigator is Jerome Jourquin, Ph.D., M.S. at Susan G. Komen. The trial plans to enroll 200,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology